Michael Hayden Publications

  1. Caron, NS, Southwell, AL, Brouwers, CC, Cengio, LD, Xie, Y, Black, HF et al.. Potent and sustained huntingtin lowering via AAV5 encoding miRNA preserves striatal volume and cognitive function in a humanized mouse model of Huntington disease. Nucleic Acids Res. 2020;48 (1):36-54. doi: 10.1093/nar/gkz976. PubMed PMID:31745548 .
  2. Kay, C, Collins, JA, Caron, NS, Agostinho, LA, Findlay-Black, H, Casal, L et al.. A Comprehensive Haplotype-Targeting Strategy for Allele-Specific HTT Suppression in Huntington Disease. Am. J. Hum. Genet. 2019;105 (6):1112-1125. doi: 10.1016/j.ajhg.2019.10.011. PubMed PMID:31708117 PubMed Central PMC6904807.
  3. Winther, M, Shpitzen, S, Yaacov, O, Landau, J, Oren, L, Foroozan-Rosenberg, L et al.. In search of a genetic explanation for LDLc variability in an FH family: common SNPs and a rare mutation in MTTP explain only part of LDL variability in an FH family. J. Lipid Res. 2019;60 (10):1733-1740. doi: 10.1194/jlr.M092049. PubMed PMID:31387896 PubMed Central PMC6795082.
  4. Ehrnhoefer, DE, Skotte, NH, Reinshagen, J, Qiu, X, Windshügel, B, Jaishankar, P et al.. Activation of Caspase-6 Is Promoted by a Mutant Huntingtin Fragment and Blocked by an Allosteric Inhibitor Compound. Cell Chem Biol. 2019;26 (9):1295-1305.e6. doi: 10.1016/j.chembiol.2019.07.001. PubMed PMID:31353319 PubMed Central PMC6754302.
  5. Smith-Dijak, AI, Nassrallah, WB, Zhang, LYJ, Geva, M, Hayden, MR, Raymond, LA et al.. Impairment and Restoration of Homeostatic Plasticity in Cultured Cortical Neurons From a Mouse Model of Huntington Disease. Front Cell Neurosci. 2019;13 :209. doi: 10.3389/fncel.2019.00209. PubMed PMID:31156395 PubMed Central PMC6532531.
  6. Eddings, CR, Arbez, N, Akimov, S, Geva, M, Hayden, MR, Ross, CA et al.. Pridopidine protects neurons from mutant-huntingtin toxicity via the sigma-1 receptor. Neurobiol. Dis. 2019;129 :118-129. doi: 10.1016/j.nbd.2019.05.009. PubMed PMID:31108174 .
  7. Wright, GEB, Collins, JA, Kay, C, McDonald, C, Dolzhenko, E, Xia, Q et al.. Length of Uninterrupted CAG, Independent of Polyglutamine Size, Results in Increased Somatic Instability, Hastening Onset of Huntington Disease. Am. J. Hum. Genet. 2019;104 (6):1116-1126. doi: 10.1016/j.ajhg.2019.04.007. PubMed PMID:31104771 PubMed Central PMC6556907.
  8. Ferrari Bardile, C, Garcia-Miralles, M, Caron, NS, Rayan, NA, Langley, SR, Harmston, N et al.. Intrinsic mutant HTT-mediated defects in oligodendroglia cause myelination deficits and behavioral abnormalities in Huntington disease. Proc. Natl. Acad. Sci. U.S.A. 2019;116 (19):9622-9627. doi: 10.1073/pnas.1818042116. PubMed PMID:31015293 PubMed Central PMC6511031.
  9. Ellrichmann, G, Blusch, A, Fatoba, O, Brunner, J, Reick, C, Hayardeny, L et al.. Author Correction: Laquinimod treatment in the R6/2 mouse model. Sci Rep. 2019;9 (1):4960. doi: 10.1038/s41598-018-37926-4. PubMed PMID:30874566 PubMed Central PMC6420624.
  10. Kang, R, Wang, L, Sanders, SS, Zuo, K, Hayden, MR, Raymond, LA et al.. Altered Regulation of Striatal Neuronal N-Methyl-D-Aspartate Receptor Trafficking by Palmitoylation in Huntington Disease Mouse Model. Front Synaptic Neurosci. 2019;11 :3. doi: 10.3389/fnsyn.2019.00003. PubMed PMID:30846936 PubMed Central PMC6393405.
  11. Ionescu, A, Gradus, T, Altman, T, Maimon, R, Saraf Avraham, N, Geva, M et al.. Targeting the Sigma-1 Receptor via Pridopidine Ameliorates Central Features of ALS Pathology in a SOD1G93A Model. Cell Death Dis. 2019;10 (3):210. doi: 10.1038/s41419-019-1451-2. PubMed PMID:30824685 PubMed Central PMC6397200.
  12. Francardo, V, Geva, M, Bez, F, Denis, Q, Steiner, L, Hayden, MR et al.. Pridopidine Induces Functional Neurorestoration Via the Sigma-1 Receptor in a Mouse Model of Parkinson's Disease. Neurotherapeutics. 2019;16 (2):465-479. doi: 10.1007/s13311-018-00699-9. PubMed PMID:30756361 PubMed Central PMC6554374.
  13. Ryskamp, D, Wu, L, Wu, J, Kim, D, Rammes, G, Geva, M et al.. Pridopidine stabilizes mushroom spines in mouse models of Alzheimer's disease by acting on the sigma-1 receptor. Neurobiol. Dis. 2019;124 :489-504. doi: 10.1016/j.nbd.2018.12.022. PubMed PMID:30594810 PubMed Central PMC6363865.
  14. Johnston, TH, Geva, M, Steiner, L, Orbach, A, Papapetropoulos, S, Savola, JM et al.. Pridopidine, a clinic-ready compound, reduces 3,4-dihydroxyphenylalanine-induced dyskinesia in Parkinsonian macaques. Mov. Disord. 2019;34 (5):708-716. doi: 10.1002/mds.27565. PubMed PMID:30575996 .
  15. Reilmann, R, McGarry, A, Grachev, ID, Savola, JM, Borowsky, B, Eyal, E et al.. Safety and efficacy of pridopidine in patients with Huntington's disease (PRIDE-HD): a phase 2, randomised, placebo-controlled, multicentre, dose-ranging study. Lancet Neurol. 2019;18 (2):165-176. doi: 10.1016/S1474-4422(18)30391-0. PubMed PMID:30563778 .
  16. Melamed-Gal, S, Loupe, P, Timan, B, Weinstein, V, Kolitz, S, Zhang, J et al.. Response to the Letter-to-the Editor by Cohen et al. concerning our eNeurologicalSci article, Melamed-Gal, et al. Physicochemical, biological, functional and toxicological characterization of the European follow-on glatiramer acetate product as compared with Copaxone. eNeurologicalSci 2018;12:19-30.https://doi.org/10.1016/j.ensci.2018.05.006. eNeurologicalSci. 2018;13 :53-55. doi: 10.1016/j.ensci.2018.11.007. PubMed PMID:30547104 PubMed Central PMC6284183.
  17. Martin, DDO, Schmidt, ME, Nguyen, YT, Lazic, N, Hayden, MR. Identification of a novel caspase cleavage site in huntingtin that regulates mutant huntingtin clearance. FASEB J. 2019;33 (3):3190-3197. doi: 10.1096/fj.201701510RRR. PubMed PMID:30423259 .
  18. Garcia-Miralles, M, Yusof, NABM, Tan, JY, Radulescu, CI, Sidik, H, Tan, LJ et al.. Laquinimod Treatment Improves Myelination Deficits at the Transcriptional and Ultrastructural Levels in the YAC128 Mouse Model of Huntington Disease. Mol. Neurobiol. 2019;56 (6):4464-4478. doi: 10.1007/s12035-018-1393-1. PubMed PMID:30334188 .
  19. Southwell, AL, Kordasiewicz, HB, Langbehn, D, Skotte, NH, Parsons, MP, Villanueva, EB et al.. Huntingtin suppression restores cognitive function in a mouse model of Huntington's disease. Sci Transl Med. 2018;10 (461):. doi: 10.1126/scitranslmed.aar3959. PubMed PMID:30282695 .
  20. Caron, NS, Dorsey, ER, Hayden, MR. Therapeutic approaches to Huntington disease: from the bench to the clinic. Nat Rev Drug Discov. 2018;17 (10):729-750. doi: 10.1038/nrd.2018.133. PubMed PMID:30237454 .
  21. Melamed-Gal, S, Loupe, P, Timan, B, Weinstein, V, Kolitz, S, Zhang, J et al.. Physicochemical, biological, functional and toxicological characterization of the European follow-on glatiramer acetate product as compared with Copaxone. eNeurologicalSci. 2018;12 :19-30. doi: 10.1016/j.ensci.2018.05.006. PubMed PMID:30094354 PubMed Central PMC6073084.
  22. Wright, GEB, Amstutz, U, Drögemöller, BI, Shih, J, Rassekh, SR, Hayden, MR et al.. Pharmacogenomics of Vincristine-Induced Peripheral Neuropathy Implicates Pharmacokinetic and Inherited Neuropathy Genes. Clin. Pharmacol. Ther. 2019;105 (2):402-410. doi: 10.1002/cpt.1179. PubMed PMID:29999516 PubMed Central PMC6519044.
  23. Schmidt, ME, Buren, C, Mackay, JP, Cheung, D, Dal Cengio, L, Raymond, LA et al.. Altering cortical input unmasks synaptic phenotypes in the YAC128 cortico-striatal co-culture model of Huntington disease. BMC Biol. 2018;16 (1):58. doi: 10.1186/s12915-018-0526-3. PubMed PMID:29945611 PubMed Central PMC6020351.
  24. Martin, DDO, Kay, C, Collins, JA, Nguyen, YT, Slama, RA, Hayden, MR et al.. A human huntingtin SNP alters post-translational modification and pathogenic proteolysis of the protein causing Huntington disease. Sci Rep. 2018;8 (1):8096. doi: 10.1038/s41598-018-25903-w. PubMed PMID:29802276 PubMed Central PMC5970160.
  25. Kusko, R, Dreymann, J, Ross, J, Cha, Y, Escalante-Chong, R, Garcia-Miralles, M et al.. Large-scale transcriptomic analysis reveals that pridopidine reverses aberrant gene expression and activates neuroprotective pathways in the YAC128 HD mouse. Mol Neurodegener. 2018;13 (1):25. doi: 10.1186/s13024-018-0259-3. PubMed PMID:29783994 PubMed Central PMC5963017.
  26. Petrella, LI, Castelhano, JM, Ribeiro, M, Sereno, JV, Gonçalves, SI, Laço, MN et al.. A whole brain longitudinal study in the YAC128 mouse model of Huntington's disease shows distinct trajectories of neurochemical, structural connectivity and volumetric changes. Hum. Mol. Genet. 2018;27 (12):2125-2137. doi: 10.1093/hmg/ddy119. PubMed PMID:29668904 .
  27. Ladha, S, Qiu, X, Casal, L, Caron, NS, Ehrnhoefer, DE, Hayden, MR et al.. Constitutive ablation of caspase-6 reduces the inflammatory response and behavioural changes caused by peripheral pro-inflammatory stimuli. Cell Death Discov. 2018;4 :40. doi: 10.1038/s41420-018-0043-8. PubMed PMID:29560279 PubMed Central PMC5849887.
  28. Ehrnhoefer, DE, Martin, DDO, Schmidt, ME, Qiu, X, Ladha, S, Caron, NS et al.. Preventing mutant huntingtin proteolysis and intermittent fasting promote autophagy in models of Huntington disease. Acta Neuropathol Commun. 2018;6 (1):16. doi: 10.1186/s40478-018-0518-0. PubMed PMID:29510748 PubMed Central PMC5839066.
  29. Chevre, R, Trigueros-Motos, L, Castaño, D, Chua, T, Corlianò, M, Patankar, JV et al.. Therapeutic modulation of the bile acid pool by Cyp8b1 knockdown protects against nonalcoholic fatty liver disease in mice. FASEB J. 2018;32 (7):3792-3802. doi: 10.1096/fj.201701084RR. PubMed PMID:29481310 .
  30. Kay, C, Collins, JA, Wright, GEB, Baine, F, Miedzybrodzka, Z, Aminkeng, F et al.. The molecular epidemiology of Huntington disease is related to intermediate allele frequency and haplotype in the general population. Am. J. Med. Genet. B Neuropsychiatr. Genet. 2018;177 (3):346-357. doi: 10.1002/ajmg.b.32618. PubMed PMID:29460498 .
  31. Drögemöller, BI, Brooks, B, Critchley, C, Monzon, JG, Wright, GEB, Liu, G et al.. Further Investigation of the Role of ACYP2 and WFS1 Pharmacogenomic Variants in the Development of Cisplatin-Induced Ototoxicity in Testicular Cancer Patients. Clin. Cancer Res. 2018;24 (8):1866-1871. doi: 10.1158/1078-0432.CCR-17-2810. PubMed PMID:29358504 .
  32. Garcia-Miralles, M, Geva, M, Tan, JY, Yusof, NABM, Cha, Y, Kusko, R et al.. Early pridopidine treatment improves behavioral and transcriptional deficits in YAC128 Huntington disease mice. JCI Insight. 2017;2 (23):. doi: 10.1172/jci.insight.95665. PubMed PMID:29212949 PubMed Central PMC5752291.
  33. Grossman, I, Kolitz, S, Komlosh, A, Zeskind, B, Weinstein, V, Laifenfeld, D et al.. Compositional differences between Copaxone and Glatopa are reflected in altered immunomodulation ex vivo in a mouse model. Ann. N. Y. Acad. Sci. 2017;1407 (1):75-89. doi: 10.1111/nyas.13547. PubMed PMID:29168242 .
  34. Ehrnhoefer, DE, Southwell, AL, Sivasubramanian, M, Qiu, X, Villanueva, EB, Xie, Y et al.. HACE1 is essential for astrocyte mitochondrial function and influences Huntington disease phenotypes in vivo. Hum. Mol. Genet. 2018;27 (2):239-253. doi: 10.1093/hmg/ddx394. PubMed PMID:29121340 PubMed Central PMC5886116.
  35. Kay, C, Hayden, MR, Leavitt, BR. Epidemiology of Huntington disease. Handb Clin Neurol. 2017;144 :31-46. doi: 10.1016/B978-0-12-801893-4.00003-1. PubMed PMID:28947124 .
  36. Silva, AC, Ferreira, IL, Hayden, MR, Ferreiro, E, Rego, AC. Characterization of subventricular zone-derived progenitor cells from mild and late symptomatic YAC128 mouse model of Huntington's disease. Biochim Biophys Acta Mol Basis Dis. 2018;1864 (1):34-44. doi: 10.1016/j.bbadis.2017.09.009. PubMed PMID:28939435 .
  37. Lambinet, V, Hayden, ME, Reid, C, Gries, G. Honey bees possess a polarity-sensitive magnetoreceptor. J. Comp. Physiol. A Neuroethol. Sens. Neural. Behav. Physiol. 2017;203 (12):1029-1036. doi: 10.1007/s00359-017-1214-4. PubMed PMID:28916947 .
  38. Trigueros-Motos, L, van Capelleveen, JC, Torta, F, Castaño, D, Zhang, LH, Chai, EC et al.. ABCA8 Regulates Cholesterol Efflux and High-Density Lipoprotein Cholesterol Levels. Arterioscler. Thromb. Vasc. Biol. 2017;37 (11):2147-2155. doi: 10.1161/ATVBAHA.117.309574. PubMed PMID:28882873 .
  39. McGarry, A, Kieburtz, K, Abler, V, Grachev, ID, Gandhi, S, Auinger, P et al.. Safety and Exploratory Efficacy at 36 Months in Open-HART, an Open-Label Extension Study of Pridopidine in Huntington's Disease. J Huntingtons Dis. 2017;6 (3):189-199. doi: 10.3233/JHD-170241. PubMed PMID:28826192 .
  40. Ellrichmann, G, Blusch, A, Fatoba, O, Brunner, J, Reick, C, Hayardeny, L et al.. Laquinimod treatment in the R6/2 mouse model. Sci Rep. 2017;7 (1):4947. doi: 10.1038/s41598-017-04990-1. PubMed PMID:28694434 PubMed Central PMC5504033.
  41. Ross, CJ, Towfic, F, Shankar, J, Laifenfeld, D, Thoma, M, Davis, M et al.. A pharmacogenetic signature of high response to Copaxone in late-phase clinical-trial cohorts of multiple sclerosis. Genome Med. 2017;9 (1):50. doi: 10.1186/s13073-017-0436-y. PubMed PMID:28569182 PubMed Central PMC5450152.
  42. Drögemöller, BI, Monzon, JG, Bhavsar, AP, Borrie, AE, Brooks, B, Wright, GEB et al.. Association Between SLC16A5 Genetic Variation and Cisplatin-Induced Ototoxic Effects in Adult Patients With Testicular Cancer. JAMA Oncol. 2017;3 (11):1558-1562. doi: 10.1001/jamaoncol.2017.0502. PubMed PMID:28448657 PubMed Central PMC5824214.
  43. Martin, DDO, Hayden, MR. Neurodegeneration: Role of repeats in protein clearance. Nature. 2017;545 (7652):33-34. doi: 10.1038/nature22489. PubMed PMID:28445458 .
  44. Lambinet, V, Hayden, ME, Reigl, K, Gomis, S, Gries, G. Linking magnetite in the abdomen of honey bees to a magnetoreceptive function. Proc. Biol. Sci. 2017;284 (1851):. doi: 10.1098/rspb.2016.2873. PubMed PMID:28330921 PubMed Central PMC5378088.
  45. Aminkeng, F, Ross, CJD, Rassekh, SR, Rieder, MJ, Bhavsar, AP, Sanatani, S et al.. Pharmacogenomic screening for anthracycline-induced cardiotoxicity in childhood cancer. Br J Clin Pharmacol. 2017;83 (5):1143-1145. doi: 10.1111/bcp.13218. PubMed PMID:28317142 PubMed Central PMC5401971.
  46. Naia, L, Cunha-Oliveira, T, Rodrigues, J, Rosenstock, TR, Oliveira, A, Ribeiro, M et al.. Histone Deacetylase Inhibitors Protect Against Pyruvate Dehydrogenase Dysfunction in Huntington's Disease. J. Neurosci. 2017;37 (10):2776-2794. doi: 10.1523/JNEUROSCI.2006-14.2016. PubMed PMID:28123081 PubMed Central PMC6596633.
  47. Southwell, AL, Skotte, NH, Villanueva, EB, Østergaard, ME, Gu, X, Kordasiewicz, HB et al.. A novel humanized mouse model of Huntington disease for preclinical development of therapeutics targeting mutant huntingtin alleles. Hum. Mol. Genet. 2017;26 (6):1115-1132. doi: 10.1093/hmg/ddx021. PubMed PMID:28104789 .
  48. Hayden, MR, Kay, C. Author response: Huntington disease reduced penetrance alleles occur at high frequency in the general population. Neurology. 2017;88 (3):334-335. doi: 10.1212/WNL.0000000000003528. PubMed PMID:28093515 .
  49. Kay, C, Tirado-Hurtado, I, Cornejo-Olivas, M, Collins, JA, Wright, G, Inca-Martinez, M et al.. The targetable A1 Huntington disease haplotype has distinct Amerindian and European origins in Latin America. Eur. J. Hum. Genet. 2017;25 (3):332-340. doi: 10.1038/ejhg.2016.169. PubMed PMID:28000697 PubMed Central PMC5315506.
  50. Sanders, SS, Parsons, MP, Mui, KK, Southwell, AL, Franciosi, S, Cheung, D et al.. Sudden death due to paralysis and synaptic and behavioral deficits when Hip14/Zdhhc17 is deleted in adult mice. BMC Biol. 2016;14 (1):108. doi: 10.1186/s12915-016-0333-7. PubMed PMID:27927242 PubMed Central PMC5142322.
  51. Skotte, NH, Sanders, SS, Singaraja, RR, Ehrnhoefer, DE, Vaid, K, Qiu, X et al.. Palmitoylation of caspase-6 by HIP14 regulates its activation. Cell Death Differ. 2017;24 (3):433-444. doi: 10.1038/cdd.2016.139. PubMed PMID:27911442 PubMed Central PMC5344205.
  52. Ryskamp, D, Wu, J, Geva, M, Kusko, R, Grossman, I, Hayden, M et al.. The sigma-1 receptor mediates the beneficial effects of pridopidine in a mouse model of Huntington disease. Neurobiol. Dis. 2017;97 (Pt A):46-59. doi: 10.1016/j.nbd.2016.10.006. PubMed PMID:27818324 PubMed Central PMC5214572.
  53. Wright, GEB, Carleton, B, Hayden, MR, Ross, CJD. The global spectrum of protein-coding pharmacogenomic diversity. Pharmacogenomics J. 2018;18 (1):187-195. doi: 10.1038/tpj.2016.77. PubMed PMID:27779249 PubMed Central PMC5817389.
  54. Jan, A, Jansonius, B, Delaidelli, A, Somasekharan, SP, Bhanshali, F, Vandal, M et al.. eEF2K inhibition blocks Aβ42 neurotoxicity by promoting an NRF2 antioxidant response. Acta Neuropathol. 2017;133 (1):101-119. doi: 10.1007/s00401-016-1634-1. PubMed PMID:27752775 .
  55. Kaye, J, Piryatinsky, V, Birnberg, T, Hingaly, T, Raymond, E, Kashi, R et al.. Laquinimod arrests experimental autoimmune encephalomyelitis by activating the aryl hydrocarbon receptor. Proc. Natl. Acad. Sci. U.S.A. 2016;113 (41):E6145-E6152. doi: 10.1073/pnas.1607843113. PubMed PMID:27671624 PubMed Central PMC5068259.
  56. Naia, L, Rosenstock, TR, Oliveira, AM, Oliveira-Sousa, SI, Caldeira, GL, Carmo, C et al.. Comparative Mitochondrial-Based Protective Effects of Resveratrol and Nicotinamide in Huntington's Disease Models. Mol. Neurobiol. 2017;54 (7):5385-5399. doi: 10.1007/s12035-016-0048-3. PubMed PMID:27590140 .
  57. Garcia-Miralles, M, Hong, X, Tan, LJ, Caron, NS, Huang, Y, To, XV et al.. Laquinimod rescues striatal, cortical and white matter pathology and results in modest behavioural improvements in the YAC128 model of Huntington disease. Sci Rep. 2016;6 :31652. doi: 10.1038/srep31652. PubMed PMID:27528441 PubMed Central PMC4985819.
  58. Geva, M, Kusko, R, Soares, H, Fowler, KD, Birnberg, T, Barash, S et al.. Pridopidine activates neuroprotective pathways impaired in Huntington Disease. Hum. Mol. Genet. 2016;25 (18):3975-3987. doi: 10.1093/hmg/ddw238. PubMed PMID:27466197 PubMed Central PMC5291233.
  59. Southwell, AL, Smith-Dijak, A, Kay, C, Sepers, M, Villanueva, EB, Parsons, MP et al.. An enhanced Q175 knock-in mouse model of Huntington disease with higher mutant huntingtin levels and accelerated disease phenotypes. Hum. Mol. Genet. 2016;25 (17):3654-3675. doi: 10.1093/hmg/ddw212. PubMed PMID:27378694 PubMed Central PMC5216613.
  60. Kay, C, Collins, JA, Miedzybrodzka, Z, Madore, SJ, Gordon, ES, Gerry, N et al.. Huntington disease reduced penetrance alleles occur at high frequency in the general population. Neurology. 2016;87 (3):282-8. doi: 10.1212/WNL.0000000000002858. PubMed PMID:27335115 PubMed Central PMC4955276.
  61. Ehrnhoefer, DE, Caron, NS, Deng, Y, Qiu, X, Tsang, M, Hayden, MR et al.. Laquinimod decreases Bax expression and reduces caspase-6 activation in neurons. Exp. Neurol. 2016;283 (Pt A):121-8. doi: 10.1016/j.expneurol.2016.06.008. PubMed PMID:27296315 .
  62. Hayden, M. A true mentor and pioneer in medical genetics. S. Afr. Med. J. 2016;106 (6 Suppl 1):S7-9. doi: 10.7196/SAMJ.2016.v106i6.11022. PubMed PMID:27245547 .
  63. Aminkeng, F, Ross, CJ, Rassekh, SR, Hwang, S, Rieder, MJ, Bhavsar, AP et al.. Recommendations for genetic testing to reduce the incidence of anthracycline-induced cardiotoxicity. Br J Clin Pharmacol. 2016;82 (3):683-95. doi: 10.1111/bcp.13008. PubMed PMID:27197003 PubMed Central PMC5338111.
  64. Masellis, M, Collinson, S, Freeman, N, Tampakeras, M, Levy, J, Tchelet, A et al.. Dopamine D2 receptor gene variants and response to rasagiline in early Parkinson's disease: a pharmacogenetic study. Brain. 2016;139 (Pt 7):2050-62. doi: 10.1093/brain/aww109. PubMed PMID:27190009 .
  65. Maillet, A, Tan, K, Chai, X, Sadananda, SN, Mehta, A, Ooi, J et al.. Modeling Doxorubicin-Induced Cardiotoxicity in Human Pluripotent Stem Cell Derived-Cardiomyocytes. Sci Rep. 2016;6 :25333. doi: 10.1038/srep25333. PubMed PMID:27142468 PubMed Central PMC4855185.
  66. Teo, RT, Hong, X, Yu-Taeger, L, Huang, Y, Tan, LJ, Xie, Y et al.. Structural and molecular myelination deficits occur prior to neuronal loss in the YAC128 and BACHD models of Huntington disease. Hum. Mol. Genet. 2016;25 (13):2621-2632. doi: 10.1093/hmg/ddw122. PubMed PMID:27126634 PubMed Central PMC5181633.
  67. Connolly, C, Magnusson-Lind, A, Lu, G, Wagner, PK, Southwell, AL, Hayden, MR et al.. Enhanced immune response to MMP3 stimulation in microglia expressing mutant huntingtin. Neuroscience. 2016;325 :74-88. doi: 10.1016/j.neuroscience.2016.03.031. PubMed PMID:27033979 .
  68. Miniarikova, J, Zanella, I, Huseinovic, A, van der Zon, T, Hanemaaijer, E, Martier, R et al.. Design, Characterization, and Lead Selection of Therapeutic miRNAs Targeting Huntingtin for Development of Gene Therapy for Huntington's Disease. Mol Ther Nucleic Acids. 2016;5 :e297. doi: 10.1038/mtna.2016.7. PubMed PMID:27003755 PubMed Central PMC5014463.
  69. Wijesekara, N, Kaur, A, Westwell-Roper, C, Nackiewicz, D, Soukhatcheva, G, Hayden, MR et al.. ABCA1 deficiency and cellular cholesterol accumulation increases islet amyloidogenesis in mice. Diabetologia. 2016;59 (6):1242-6. doi: 10.1007/s00125-016-3907-6. PubMed PMID:26970755 .
  70. Grossman, I, Knappertz, V, Laifenfeld, D, Ross, C, Zeskind, B, Kolitz, S et al.. Pharmacogenomics strategies to optimize treatments for multiple sclerosis: Insights from clinical research. Prog. Neurobiol. 2017;152 :114-130. doi: 10.1016/j.pneurobio.2016.02.001. PubMed PMID:26952809 .
  71. Riechers, SP, Butland, S, Deng, Y, Skotte, N, Ehrnhoefer, DE, Russ, J et al.. Interactome network analysis identifies multiple caspase-6 interactors involved in the pathogenesis of HD. Hum. Mol. Genet. 2016;25 (8):1600-18. doi: 10.1093/hmg/ddw036. PubMed PMID:26908611 .
  72. Naia, L, Ribeiro, M, Rodrigues, J, Duarte, AI, Lopes, C, Rosenstock, TR et al.. Insulin and IGF-1 regularize energy metabolites in neural cells expressing full-length mutant huntingtin. Neuropeptides. 2016;58 :73-81. doi: 10.1016/j.npep.2016.01.009. PubMed PMID:26876526 .
  73. Garcia-Miralles, M, Ooi, J, Ferrari Bardile, C, Tan, LJ, George, M, Drum, CL et al.. Treatment with the MAO-A inhibitor clorgyline elevates monoamine neurotransmitter levels and improves affective phenotypes in a mouse model of Huntington disease. Exp. Neurol. 2016;278 :4-10. doi: 10.1016/j.expneurol.2016.01.019. PubMed PMID:26825854 .
  74. Dobson, L, Träger, U, Farmer, R, Hayardeny, L, Loupe, P, Hayden, MR et al.. Laquinimod dampens hyperactive cytokine production in Huntington's disease patient myeloid cells. J. Neurochem. 2016;137 (5):782-94. doi: 10.1111/jnc.13553. PubMed PMID:26823290 PubMed Central PMC4982105.
  75. Hasson, T, Kolitz, S, Towfic, F, Laifenfeld, D, Bakshi, S, Beriozkin, O et al.. Functional effects of the antigen glatiramer acetate are complex and tightly associated with its composition. J. Neuroimmunol. 2016;290 :84-95. doi: 10.1016/j.jneuroim.2015.11.020. PubMed PMID:26711576 .
  76. Chan, SL, Samaranayake, N, Ross, CJ, Toh, MT, Carleton, B, Hayden, MR et al.. Genetic diversity of variants involved in drug response and metabolism in Sri Lankan populations: implications for clinical implementation of pharmacogenomics. Pharmacogenet. Genomics. 2016;26 (1):28-39. doi: 10.1097/FPC.0000000000000182. PubMed PMID:26444257 PubMed Central PMC4890825.
  77. Patankar, JV, Brunham, LR, Hayden, MR. Comment on Rickels et al. Loss-of-Function Mutations in ABCA1 and Enhanced β-Cell Secretory Capacity in Young Adults. Diabetes 2015;64:193-199. Diabetes. 2015;64 (9):e25-6; discussion e27. doi: 10.2337/db15-0518. PubMed PMID:26294435 .
  78. Sanders, SS, Martin, DD, Butland, SL, Lavallée-Adam, M, Calzolari, D, Kay, C et al.. Curation of the Mammalian Palmitoylome Indicates a Pivotal Role for Palmitoylation in Diseases and Disorders of the Nervous System and Cancers. PLoS Comput. Biol. 2015;11 (8):e1004405. doi: 10.1371/journal.pcbi.1004405. PubMed PMID:26275289 PubMed Central PMC4537140.
  79. Sadananda, SN, Foo, JN, Toh, MT, Cermakova, L, Trigueros-Motos, L, Chan, T et al.. Targeted next-generation sequencing to diagnose disorders of HDL cholesterol. J. Lipid Res. 2015;56 (10):1993-2001. doi: 10.1194/jlr.P058891. PubMed PMID:26255038 PubMed Central PMC4583092.
  80. Aminkeng, F, Bhavsar, AP, Visscher, H, Rassekh, SR, Li, Y, Lee, JW et al.. A coding variant in RARG confers susceptibility to anthracycline-induced cardiotoxicity in childhood cancer. Nat. Genet. 2015;47 (9):1079-84. doi: 10.1038/ng.3374. PubMed PMID:26237429 PubMed Central PMC4552570.
  81. Visscher, H, Rassekh, SR, Sandor, GS, Caron, HN, van Dalen, EC, Kremer, LC et al.. Genetic variants in SLC22A17 and SLC22A7 are associated with anthracycline-induced cardiotoxicity in children. Pharmacogenomics. 2015;16 (10):1065-76. doi: 10.2217/pgs.15.61. PubMed PMID:26230641 .
  82. Kay, C, Collins, JA, Skotte, NH, Southwell, AL, Warby, SC, Caron, NS et al.. Huntingtin Haplotypes Provide Prioritized Target Panels for Allele-specific Silencing in Huntington Disease Patients of European Ancestry. Mol. Ther. 2015;23 (11):1759-1771. doi: 10.1038/mt.2015.128. PubMed PMID:26201449 PubMed Central PMC4817952.
  83. Shaw, K, Amstutz, U, Kim, RB, Lesko, LJ, Turgeon, J, Michaud, V et al.. Clinical Practice Recommendations on Genetic Testing of CYP2C9 and VKORC1 Variants in Warfarin Therapy. Ther Drug Monit. 2015;37 (4):428-36. doi: 10.1097/FTD.0000000000000192. PubMed PMID:26186657 .
  84. Southwell, AL, Smith, SE, Davis, TR, Caron, NS, Villanueva, EB, Xie, Y et al.. Ultrasensitive measurement of huntingtin protein in cerebrospinal fluid demonstrates increase with Huntington disease stage and decrease following brain huntingtin suppression. Sci Rep. 2015;5 :12166. doi: 10.1038/srep12166. PubMed PMID:26174131 PubMed Central PMC4502413.
  85. Hitchcock, E, Patankar, JV, Tyson, C, Hrynchak, M, Hayden, MR, Gibson, WT et al.. A novel microdeletion affecting the CETP gene raises HDL-associated cholesterol levels. Clin. Genet. 2016;89 (4):495-500. doi: 10.1111/cge.12633. PubMed PMID:26126777 .
  86. Kolitz, S, Hasson, T, Towfic, F, Funt, JM, Bakshi, S, Fowler, KD et al.. Gene expression studies of a human monocyte cell line identify dissimilarities between differently manufactured glatiramoids. Sci Rep. 2015;5 :10191. doi: 10.1038/srep10191. PubMed PMID:25998228 PubMed Central PMC4441120.
  87. Jan, A, Karasinska, JM, Kang, MH, de Haan, W, Ruddle, P, Kaur, A et al.. Direct intracerebral delivery of a miR-33 antisense oligonucleotide into mouse brain increases brain ABCA1 expression. [Corrected]. Neurosci. Lett. 2015;598 :66-72. doi: 10.1016/j.neulet.2015.05.007. PubMed PMID:25957561 .
  88. Bečanović, K, Nørremølle, A, Neal, SJ, Kay, C, Collins, JA, Arenillas, D et al.. A SNP in the HTT promoter alters NF-κB binding and is a bidirectional genetic modifier of Huntington disease. Nat. Neurosci. 2015;18 (6):807-16. doi: 10.1038/nn.4014. PubMed PMID:25938884 .
  89. Stroedicke, M, Bounab, Y, Strempel, N, Klockmeier, K, Yigit, S, Friedrich, RP et al.. Systematic interaction network filtering identifies CRMP1 as a novel suppressor of huntingtin misfolding and neurotoxicity. Genome Res. 2015;25 (5):701-13. doi: 10.1101/gr.182444.114. PubMed PMID:25908449 PubMed Central PMC4417118.
  90. Martin, DD, Hayden, MR. Post-translational myristoylation at the cross roads of cell death, autophagy and neurodegeneration. Biochem. Soc. Trans. 2015;43 (2):229-34. doi: 10.1042/BST20140281. PubMed PMID:25849922 .
  91. Sanders, SS, Hayden, MR. Aberrant palmitoylation in Huntington disease. Biochem. Soc. Trans. 2015;43 (2):205-10. doi: 10.1042/BST20140242. PubMed PMID:25849918 .
  92. Mattis, VB, Tom, C, Akimov, S, Saeedian, J, Østergaard, ME, Southwell, AL et al.. HD iPSC-derived neural progenitors accumulate in culture and are susceptible to BDNF withdrawal due to glutamate toxicity. Hum. Mol. Genet. 2015;24 (11):3257-71. doi: 10.1093/hmg/ddv080. PubMed PMID:25740845 PubMed Central PMC4424959.
  93. Sturrock, A, Laule, C, Wyper, K, Milner, RA, Decolongon, J, Dar Santos, R et al.. A longitudinal study of magnetic resonance spectroscopy Huntington's disease biomarkers. Mov. Disord. 2015;30 (3):393-401. doi: 10.1002/mds.26118. PubMed PMID:25690257 .
  94. Southwell, AL, Franciosi, S, Villanueva, EB, Xie, Y, Winter, LA, Veeraraghavan, J et al.. Anti-semaphorin 4D immunotherapy ameliorates neuropathology and some cognitive impairment in the YAC128 mouse model of Huntington disease. Neurobiol. Dis. 2015;76 :46-56. doi: 10.1016/j.nbd.2015.01.002. PubMed PMID:25662335 .
  95. Østergaard, ME, Thomas, G, Koller, E, Southwell, AL, Hayden, MR, Seth, PP et al.. Biophysical and biological characterization of hairpin and molecular beacon RNase H active antisense oligonucleotides. ACS Chem. Biol. 2015;10 (5):1227-33. doi: 10.1021/cb500880f. PubMed PMID:25654188 .
  96. Aharony, I, Ehrnhoefer, DE, Shruster, A, Qiu, X, Franciosi, S, Hayden, MR et al.. A Huntingtin-based peptide inhibitor of caspase-6 provides protection from mutant Huntingtin-induced motor and behavioral deficits. Hum. Mol. Genet. 2015;24 (9):2604-14. doi: 10.1093/hmg/ddv023. PubMed PMID:25616965 PubMed Central PMC4383866.
  97. Brunham, LR, Hayden, MR. Human genetics of HDL: Insight into particle metabolism and function. Prog. Lipid Res. 2015;58 :14-25. doi: 10.1016/j.plipres.2015.01.001. PubMed PMID:25601427 .
  98. Wong, BKY, Ehrnhoefer, DE, Graham, RK, Martin, DDO, Ladha, S, Uribe, V et al.. Partial rescue of some features of Huntington Disease in the genetic absence of caspase-6 in YAC128 mice. Neurobiol. Dis. 2015;76 :24-36. doi: 10.1016/j.nbd.2014.12.030. PubMed PMID:25583186 .
  99. Bates, GP, Dorsey, R, Gusella, JF, Hayden, MR, Kay, C, Leavitt, BR et al.. Huntington disease. Nat Rev Dis Primers. 2015;1 :15005. doi: 10.1038/nrdp.2015.5. PubMed PMID:27188817 .
  100. Sanders, SS, Hou, J, Sutton, LM, Garside, VC, Mui, KK, Singaraja, RR et al.. Huntingtin interacting proteins 14 and 14-like are required for chorioallantoic fusion during early placental development. Dev. Biol. 2015;397 (2):257-66. doi: 10.1016/j.ydbio.2014.11.018. PubMed PMID:25478910 .
Search PubMed